San Francisco 15:23:31
Cologne 00:23:31
Cape Town 01:23:31
Dubai 03:23:31
28th. November 2008
Zhang LP, Nie Q, Kang JB, Wang B, Cai CL, Li JG, Qi WJ.
Department of Radiation Oncology, Naval General Hospital of PLA, Beijing,
100037, P. R. China. drwangbin@hotmail.com.
BACKGROUND & OBJECTIVE: Radiotherapy and chemotherapy are major therapies
for locally advanced pancreatic cancer. This study was to evaluate the
efficacy of three-dimensional conformal gamma-knife radiotherapy combined
with thermochemotherapy on locally advanced pancreatic cancer. METHODS: From
December 2001 to January 2006, 75 patients with locally advanced pancreatic
cancer were divided into radiotherapy group (37 patients) and combination
group (38 patients). All patients received gamma-knife radiotherapy using
Stereotactic Radiotherapy Gamma Rays System, with iso-dose curves of 50%-60%,
tumor encircling dose of 3.0-4.5 Gy per fraction, 8-11 fractions. The
patients in combination group received simultaneous thermotherapy at
41.5-43.5 celsius (1 h/fraction, twice a week for 6 times), and chemotherapy
with venous administration of tegafur (0.5-1.0 g) and calcium folinate (CF,
0.2 g) for 4-6 times, or venous administration of gemcitabine (0.6-1.0
g/m(2)) on Days 1 and 8 and cisplatin (DDP) (20-30 mg/m(2)) on Days 1-3,
repeated every 28 days for 3-6 cycles. RESULTS: At 3 months after treatment,
the total response (complete remission and partial remission) rate was 70.7%
(53/75); the response rate was 73.7% in combination group and 67.5% in
radiotherapy group. The 1-year survival rate was 48.3%, and the 2-year
survival rate was 22.1%. The 1-and 2-year survival rates were 51.2% and 26.5%
in combination group, and 45.2% and 17.6% in radiotherapy group. No serious
complications, such as perforation, bleeding and high fever, were seen during
treatment and follow-up. CONCLUSION: 3-D conformal gamma-knife radiotherapy
combined with thermochemotherapy is well tolerated and is relatively
effective for most patients with locally advanced pancreatic cancer.
14th. October 2008
Dendritic cell therapy in combination with
interferon-alpha for the treatment of metastatic renal cell carcinoma.
Immature
dendritic cells enhance antitumor effects of hyperthermia
Active
Immunotherapy of Prostate Cancer with a Focus on Dendritic Cells